{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:51:11Z","timestamp":1791190271907,"version":"4.1.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Fabry disease is a progressive, X-linked lysosomal disorder caused by\n                      <jats:italic>GLA<\/jats:italic>\n                      variants that result in dysfunctional \u03b1-galactosidase A (\u03b1-Gal A) enzyme. One treatment option is migalastat, an oral small-molecule pharmacological chaperone treatment for patients with migalastat-amenable\n                      <jats:italic>GLA<\/jats:italic>\n                      variants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, medical records were used to determine the prevalence of migalastat-amenable variants among individuals managed for Fabry disease at centers in Brazil, Argentina, and Colombia (primary endpoint). Demographic and clinical characteristics were explored using available data. Medical records of males or females of any age with a diagnosis of Fabry disease (based on genetic testing and\/or \u03b1-Gal A enzymatic activity) were eligible for inclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Data were collected for 1,196 individuals diagnosed with Fabry disease in Brazil (n = 1,000), Argentina (n = 122), and Colombia (n = 74); of these, 720 (60.2%) had migalastat-amenable\n                      <jats:italic>GLA<\/jats:italic>\n                      variants (650 [65.0%] patients in Brazil, 32 [26.2%] in Argentina, and 38 [51.4%] in Colombia). The migalastat-amenable variants differed by country with little overlap among the cohorts in Brazil, Argentina, and Colombia in the most common variants. Median age (in years) at the study reference date (July 1, 2021) for individuals with migalastat-amenable variants was 45.6, 44.1, and 21.8 years in Brazil, Argentina, and Colombia, respectively. Data on clinical characteristics were available only in Argentina and Colombia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In those for whom data were available, there appeared to be both objective and subjective manifestations of Fabry disease, as evidenced by renal impairment, cardiac involvement, and classic Fabry disease signs and symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgene.2026.1876053","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:53:11Z","timestamp":1791186791000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of migalastat-amenable variants in patients with Fabry disease from Brazil, Argentina, and Colombia: an observational study"],"prefix":"10.3389","volume":"17","author":[{"given":"Juan Manuel","family":"Politei","sequence":"first","affiliation":[{"name":"Neurology Department, SPINE Fundation","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Zarante Baham\u00f3n","sequence":"additional","affiliation":[{"name":"San Ignacio University Hospital","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[{"name":"Federal University of S\u00e3o Paulo","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afr\u00e2nio","family":"Souza De Melo","sequence":"additional","affiliation":[{"name":"Federal University of S\u00e3o Paulo","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Horacio","family":"de Sa Pereira","sequence":"additional","affiliation":[{"name":"State University of Rio de Janeiro","place":["Rio de Janeiro, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9ia","family":"Loures-Vale","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics UK Ltd.","place":["Marlow, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biliana O.","family":"Veleva-Rotse","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc.","place":["Novato, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Krusinska","sequence":"additional","affiliation":[{"name":"Amicus Therapeutics Inc.","place":["Princeton, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Lengoc","sequence":"additional","affiliation":[{"name":"BioMarin UK Ltd.","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/asn.2016090964","article-title":"Characterization of classical and nonclassical fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1220637","DOI":"10.3389\/fmed.2023.1220637","article-title":"Consensus recommendations for the treatment and management of patients with fabry disease on migalastat: a modified Delphi study","volume":"10","author":"Bichet","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.3390\/ijerph18063320","article-title":"Gastrointestinal involvement in anderson-fabry disease: a narrative review","volume":"18","author":"Caputo","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/cge.14102","article-title":"Challenging the traditional approach for interpreting genetic variants: lessons from fabry disease","volume":"101","author":"Germain","year":"2022","journal-title":"Clin. Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"101218","DOI":"10.1016\/j.ymgmr.2025.101218","article-title":"Expert review in diagnostic, therapeutic and follow-up of fabry disease in Latin America based on patient care standards","volume":"43","author":"Giugliani","year":"2025","journal-title":"Mol. Genet. Metab. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ijns9020031","article-title":"Newborn screening for fabry disease: current status of knowledge","volume":"9","author":"Gragnaniello","year":"2023","journal-title":"Int. J. Neonatal Screen"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1002\/cphg.93","article-title":"Overview of specifications to the ACMG\/AMP variant interpretation guidelines","volume":"103","author":"Harrison","year":"2019","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6782046","DOI":"10.1155\/2020\/6782046","article-title":"Gene coexpression network and module analysis across 52 human tissues","volume":"2020","author":"He","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"bbac405","DOI":"10.1093\/bib\/bbac405","article-title":"DGHNE: network enhancement-based method in identifying disease-causing genes through a heterogeneous biomedical network","volume":"23","author":"He","year":"2022","journal-title":"Brief. Bioinform"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9293896","DOI":"10.1155\/2024\/9293896","article-title":"Baseline characteristics of fabry disease \u201camenable\u201d migalastat patients in Argentinian cohort","volume":"2024","author":"Jaurretche","year":"2024","journal-title":"Glob. Health Epidemiol. Genom"},{"key":"B13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","article-title":"Safety and efficacy of pegunigalsidase alfa in patients with fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study","volume":"18","author":"Linhart","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of fabry disease: changing pattern of causes of death in FOS - Fabry outcome survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J. Med. Genet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"QJM"},{"key":"B17","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1590\/2175-8239-JBN-2022-0107en","article-title":"Genetic and phenotypic profile of fabry disease in the population of vale do Paraiba and eastern S\u00e3o Paulo","volume":"45","author":"Paz","year":"2023","journal-title":"J. Bras. Nefrol."},{"key":"B19","volume-title":"Galafold\u00ae","author":"Pint Pharma","year":"2023"},{"key":"B20","volume-title":"Galafold\u00ae","year":"2025"},{"key":"B21","volume-title":"Galafold\u00ae","year":"2025"},{"key":"B22","first-page":"322","article-title":"Fabry disease in Argentina: clinical, biochemical and molecular correlation in all reported GLA variants","volume":"85","author":"Politei","year":"2025","journal-title":"Medicina (B Aires)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"B24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1590\/2175-8239-jbn-2021-0208","article-title":"Brazilian consensus recommendations for the diagnosis, screening, and treatment of individuals with fabry disease: Committee for rare diseases - brazilian society of Nephrology\/2021","volume":"44","author":"Silva","year":"2022","journal-title":"J. Bras. Nefrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"831179","DOI":"10.3389\/fphys.2022.831179","article-title":"Sex matters: a comprehensive comparison of female and male hearts","volume":"13","author":"St Pierre","year":"2022","journal-title":"Front. Physiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"bbac072","DOI":"10.1093\/bib\/bbac072","article-title":"HyMM: hybrid method for disease-gene prediction by integrating multiscale module structure","volume":"23","author":"Xiang","year":"2022","journal-title":"Brief. Bioinform"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1876053\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:53:12Z","timestamp":1791186792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1876053\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":26,"alternative-id":["10.3389\/fgene.2026.1876053"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2026.1876053","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1876053"}}